UCPMP 2024: Pharma Promotion Compliance Guide

The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) has been a reference framework for pharma promotion in India since 2002. In 2024, the Department of Pharmaceuticals issued an updated UCPMP — the most significant revision in two decades. For pharma companies, their agency partners, and healthcare professionals who receive promotional inputs, the 2024 update changes the compliance landscape substantially.

ICG's pharma practice — built on IIT BHU pharmaceutical engineering foundations — has applied the UCPMP framework across pharma promotional campaigns since 2018. This guide covers what changed, what remains the same, and what pharma marketers must do differently under UCPMP 2024.

UCPMP Background: Voluntary or Mandatory?

The original UCPMP 2002 was a voluntary code. The 2014 revision maintained this voluntary status but added company self-declaration requirements. The 2024 update has strengthened the framework — but the question of mandatory vs voluntary status remains actively debated in the industry.

As of mid-2026:

• The Department of Pharmaceuticals has indicated its intention to make UCPMP compliance mandatory
• The Indian Pharmaceutical Alliance (IPA) and Organisation of Pharmaceutical Producers of India (OPPI) have instructed member companies to treat UCPMP 2024 as effectively mandatory
• DGCI and state drug controllers have referenced UCPMP compliance in enforcement actions

The ICG recommendation: treat UCPMP 2024 as mandatory regardless of formal legal status. The practical enforcement risk — and the reputational risk — of non-compliance is real.

Key Changes in UCPMP 2024

1. Digital and social media explicitly included The 2024 update explicitly includes digital channels — social media, email, WhatsApp, websites, and digital advertising — within the scope of the code. The 2002 code predated modern digital marketing. The 2024 code directly addresses it.

2. Stricter HCP engagement rules Healthcare professional (HCP) engagement — conferences, CME programmes, gifts, hospitality — is now more tightly defined. Key provisions:

• Gifts to HCPs: prohibited entirely (was already in earlier code, now more explicit)
• CME sponsorship: permitted only for genuine educational events through verifiable medical associations
• Hospitality: limited to meals of modest value at genuine scientific events
• Travel sponsorship: only where the HCP is a speaker or faculty member

3. Promotional content disclosure requirements All promotional materials — whether print or digital — must carry the word "Advertisement" or "Promotional Material" clearly. Scientific papers and genuine educational content are exempt, but the distinction must be documentable.

4. Medical representatives (MR) conduct standards: The 2024 code specifies conduct standards for field force in significantly more detail. MRs must:

• Carry credentials at all times
• Present only accurate, DGCI-approved product information
• Never offer inducements for prescription behaviour
• Report adverse events encountered during visits

5. Patient-facing promotion: UCPMP 2024 distinguishes between HCP-facing and patient-facing promotion. Patient-facing content for prescription drugs is heavily restricted — Schedule J restrictions apply in addition to UCPMP.

UCPMP 2024 and Schedule J: The Interaction

A frequently confused area: UCPMP governs pharma promotional conduct broadly; Schedule J restricts advertising of treatments for 54 conditions to the general public. They operate in parallel.

A pharma company promoting a drug for cancer (Schedule J) to HCPs is governed by UCPMP — detailed prescribing information, no patient outcome guarantees, disclosure of all relevant trial data. Promoting the same drug to patients (general public) violates Schedule J regardless of UCPMP compliance.

ICG's pharma clients operate under both frameworks simultaneously:

• HCP-facing: UCPMP-compliant promotional materials, CME content, clinical data communication
• Patient-facing: Schedule J-compliant service and education framing, no treatment outcome claims

ICG's Pharos Platform and UCPMP Compliance

ICG's Pharos pharma intelligence platform is designed around UCPMP compliance by architecture. The 9 Pharos modules — Scribe, Scout, Deploy, Vigil, RxFlow, RouteIQ, Gate, Signal, Pulse — each embed compliance checkpoints:

Pharos Scribe (scientific writing): generates MSL-facing clinical summaries and publication-quality manuscripts that distinguish promotional from scientific content by design.

Pharos Scout (literature monitoring): flags newly published evidence that affects promotional claims — ensuring marketed claims remain evidence-current.

Pharos Vigil (pharmacovigilance): captures and manages adverse event data in alignment with CDSCO requirements — and ensures adverse events are not suppressed in promotional materials.

Pharos Gate (promotional material approval): digital MLR (Medical-Legal-Regulatory) review workflow. Every promotional piece passes through Gate before deployment, with an auditable approval trail — which is exactly what UCPMP 2024 requires.

Pharos Deploy (campaign deployment): controls which approved materials go to which channel. Prevents un-approved or expired promotional content from reaching HCPs.

For a pharma company building UCPMP 2024 compliance infrastructure, Pharos provides an end-to-end framework that is documentable — and defensible — under enforcement scrutiny.

Practical Compliance Actions for Pharma Marketers

Immediate actions (Month 1):

• Audit all existing promotional materials against UCPMP 2024 requirements
• Ensure all digital content carries the "Advertisement" or "Promotional Material" disclosure
• Review all HCP engagement programmes against new hospitality and gift rules
• Confirm CME sponsorships are through bona fide medical associations

Short-term (Months 2-3):

• Build MLR approval workflow for all new promotional content (Pharos Gate or equivalent)
• Brief field force on updated MR conduct standards
• Update medical representative detailing materials to reflect only DGCI-approved content
• Implement adverse event reporting workflow from field force to pharmacovigilance team

Medium-term (Months 4-6):

• Implement digital content lifecycle management (expiry tracking for approved materials)
• Set up literature monitoring for evidence updates that affect promotional claims
• Annual audit against UCPMP 2024 with documented findings

IPA Enforcement Reality

The Indian Pharmaceutical Alliance manages a complaints mechanism under UCPMP. Competitor complaints are the most common driver of enforcement review. A pharma company whose promotional materials breach UCPMP — even in an apparent minor way — becomes exposed to competitor complaints that require formal response.

Beyond the IPA process, UCPMP breaches in patient-facing digital content increasingly attract media attention. A viral Instagram post by a pharma brand making an unsubstantiated claim for a Schedule J condition generates reputational damage faster than any regulatory timeline.

ICG's approach: zero non-compliant content in the first place. The cost of building compliant content is lower than the cost of managing a breach.

Why Compliance-Led Pharma Marketing Performs Better

Prism Pulse weekly comparison report showing week-over-week deltas on views, reach, interactions, saves and enquiries across the last four weeks" width="1200" height="675" loading="lazy" decoding="async" style="width:100%;height:auto;display:block;">

The evidence from ICG's pharma engagements is consistent: scientific-quality, evidence-backed content for HCPs generates better response than promotional-style content. HCPs are trained to evaluate evidence quality. Content that reads like a promotional brochure triggers scepticism. Content that reads like a peer-reviewed summary — but is produced for field force use under UCPMP — generates genuine clinical engagement.

This is why ICG's Pharos Scribe was built on IIT BHU pharmaceutical engineering foundations. The scientific writing quality matters. And it produces measurable commercial results.

ICG works with pharma clients across prescription brands, OTC products, nutraceuticals, and medical devices — all under UCPMP + Schedule J + DPDP frameworks. Typical pharma engagements run 18-24 months.

Read next on ICG

• Pharma marketing agency India
• Pharos — pharma intelligence platform
• Pharos Gate — MLR workflow